News & Events
California State Sens. Roger Niello and Ben Allen Introduce Bipartisan Bill to Expand the California Neurodegenerative Disease Registry to Include Frontotemporal Degeneration Diagnoses
Senators Roger Niello (R–Fair Oaks) and Ben Allen (D–Santa Monica) have jointly introduced legislation (Senate Bill 1047) in the California Senate that would require the California Neurodegenerative Disease Registry to…
Lessons From a Caregiver
Like a new parent, Linda Osmundson set out on her caregiving journey with no experience, she said in an essay in Today’s Caregiver. But unlike parenting, there are relatively few…
Fundraising On The Run: 7 Marathons in 7 Days on 7 Continents
Fundraising really doesn’t have to be this hard. Bryan Metoyer has just finished the World Marathon Challenge—an incredible achievement made even more meaningful by his goal in taking it on,…
US FDA Accepts Investigational New Drug Application for Coya Therapeutics’ Experimental Therapy for FTD
Biotechnology company Coya Therapeutics announced that the United States Food and Drug Administration had accepted its investigational new drug (IND) application for its COYA 302 experimental therapy for FTD. The…
Recognizing the Easily Mistaken Signs of Young-Onset Dementia
Signs of young-onset dementias such as FTD are difficult to diagnose, according to an article on The Telegraph website (paywall; one week free access with registration), because few think of…
Advancing Hope: FTD Staff attend the Amyotrophic Lateral Sclerosis Motor Neuron Disease Annual Symposium
Shana Dodge, PhD, AFTD’s Director of Research Engagement, and Kim Jenny, MS, LCGC, AFTD’s Manager of Genetic Initiatives, attended the Amyotrophic Lateral Sclerosis Motor Neuron Disease Annual Symposium, held in…
Dear HelpLine: Compulsive Sexual Behavior
Dear HelpLine, My spouse with bvFTD has some behaviors that are difficult to talk about. He is obsessed with pornography, which is very different than who he used to be.…
Prevail Therapeutics Discontinues PR006 Trial
On February 4, Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly & Co., announced the discontinuation of the PR006 “PROCLAIM” drug development program for FTD with GRN variants due…
